GOZHENKO, Anatoliy, PAVLEGA, Hanna, GOZHENKO, Olena and ZUKOW, Walery. Features of circulating in the blood desquamated endotheliocytes at the patients with ischemic heart disease and combined with hypertonic disease. Pedagogy and Psychology of Sport. 2025;24:65637. elSSN 2450-6605.
https://doi.org/10.12775/PPS.2025.24.65637
https://apcz.umk.pl/PPS/article/view/65637

The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 29.06.2024. Revised: 27.07.2025. Accepted: 27.08.2025. Published: 22.09.2025.

Features of circulating in the blood desquamated endotheliocytes at the patients with ischemic heart disease and combined with hypertonic disease

Anatoliy I. Gozhenko[1], Hanna Ye. Pavlega[1,2], Olena A. Gozhenko[1], Walery Zukow[3]

[1]Ukrainian Scientific Research Institute for Medicine of Transport, Odesa, Ukraine

[2]Medical and Natural Sciences University, Mykolaïv, Ukraine

[3]Nicolaus Copernicus University, Toruń, Poland

ORCID
AG: https://orcid.org/0000-0001-7413-4173

HP: https://orcid.org/0009-0003-6405-1026

OG: https://orcid.org/0000-0002-4071-1304

WZ: https://orcid.org/0000-0002-7675-6117

ABSTRACT

Introduction and aim. In the process of implementing the project "Nosologically determined features of the state of desquamated circulating endothelial cells and the lipid spectrum of plasma", we first conducted a comparative study of 38 patients of both sexes with stage II hypertension (AH II), which in 20 of them was accompanied by chronic alcoholism as well as 21 healthy volunteers. It was found that alcoholism is accompanied by minimal for the sample subnormal levels of markedly and terminally altered circulating endothelial cells (ACEC), LDLP cholesterol, triglycerides, prothrombin, Klimov's and Dobiásová's&Frolich's atherogenity indices, ankle-brachial index of blood pressure (as atherogenity marker) as well as glucose, platelets and leukocytes. Instead, such patients have the maximum for the sample levels of HDLP cholesterol, erythrocytes sedimentation rate, body mass index, urea and creatinine. At the same time, the levels of hemoglobin, erythrocytes and cholesterol total as well as negentropy of endotheliocytogram and lipidogram did not differ from the controls, despite the presence of AH II. Both diastolic and systolic hypertension was less

pronounced than in sober patients. The aim of this study was to determine the characteristics of CECs and plasma lipid spectrum in patients with Ischemic Heart Disease (IHD) and comorbidity IHD&AH II.

Material and methods. The object of clinical observation was 20 patients of both sexes with IHD and 44 with comorbidity IHD&AH II as well as 21 healthy volunteers. The battery of tests remained the same.

Results. In patients with comorbidity IHD&AH II the levels of ACEC in total and markedly ACEC in particular as well as systolic and diastolic BP significantly exceeded those in patients with IHD. The difference between the levels of terminally ACEC was less pronounced, but statistically significant. In contrast, patients with IHD had significantly higher levels of initially ACEC, metabolic syndrome index, total cholesterol and, especially, Klimov's atherogenity index. There were no differences between the groups regarding moderately increased levels of LDLP cholesterol, glucose and prothrombin as well as moderately decreased levels of urea and ankle-brachial index. However, in patients with IHD, a drastic increase in triglyceride levels and Dobiásová's&Frolich's atherogenity index and, to a lesser extent, body mass index was found in combination with a decrease in HDLP cholesterol and negentropy of lipidogram, while in patients with comorbidity IHD&AH II, the listed variables did not differ from the controls.

Conclusion. In the observed cohort of patients, ischemic heart disease was accompanied by a significant increase in the level of desquamated circulating endothelial cells with varying degrees of changes, especially markedly altered, and plasma atherogenicity, as well as, to a lesser extent, glycemia and prothrombin. The burden of IHD by hypertension had an ambiguous effect on the listed variables.

Keywords: desquamated plasma endothelial cells, lipid spectrum, stage II hypertension, ischemic heart disease.

Introduction

In the process of implementing the project "Nosologically determined features of the state of desquamated circulating endothelial cells and the lipid spectrum of plasma", we [Gozhenko et al, 2025] first conducted a comparative study of 38 patients of both sexes with stage II hypertension (AH II), which in 20 of them was accompanied by chronic alcoholism as well as 21 healthy volunteers. It was found that alcoholism is accompanied by minimal for the sample subnormal levels of markedly and terminally altered circulating endothelial cells (ACEC), LDLP cholesterol, triglycerides, prothrombin, Klimov's and Dobiásová's&Frolich's atherogenity indices, ankle-brachial index of blood pressure (as atherogenity marker) as well as glucose, platelets and leukocytes. Instead, such patients have the maximum for the sample levels of HDLP cholesterol, erythrocytes sedimentation rate, body mass index, urea and creatinine. At the same time, the levels of hemoglobin, erythrocytes and cholesterol total as well as negentropy of endotheliocytogram and lipidogram did not differ from the controls, despite the presence of AH II. Both diastolic and systolic hypertension was less pronounced than in sober patients.

The aim of this study was to determine the characteristics of CECs and plasma lipid spectrum in patients with Ischemic Heart Disease (IHD) and comorbidity IHD&AH II.

Research Problems, Hypotheses, and Statistical Hypotheses

The Research Problems

1. What is the relationship between circulating desquamated endothelial cells levels and the severity of atherosclerotic changes in patients with ischemic heart disease?

2. How does the combination of ischemic heart disease with stage II hypertension affect the lipid profile and atherogenic indices compared to isolated ischemic heart disease?

3. What are the predictive factors for cardiovascular events based on endothelial dysfunction markers and metabolic syndrome components in patients with comorbid conditions?

4. Does the negentropy of lipidogram serve as a reliable biomarker for assessing cardiovascular risk stratification in patients with different degrees of endothelial damage?

5. What is the discriminative power of altered circulating endothelial cells subtypes (initially, markedly, and terminally altered) in differentiating between various cardiovascular pathologies?

The Research Hypotheses

1. Patients with ischemic heart disease demonstrate significantly elevated levels of altered circulating endothelial cells, particularly markedly altered cells, compared to healthy controls, indicating enhanced endothelial dysfunction.

2. The combination of ischemic heart disease with stage II hypertension results in a distinct metabolic and endothelial profile characterized by elevated blood pressure parameters and total altered endothelial cells, but paradoxically normalized lipid atherogenic indices.

3. Higher levels of triglycerides, lower HDL cholesterol, and increased atherogenic indices (both Klimov's and Dobiášová's & Frohlich's) are associated with more severe endothelial dysfunction in patients with isolated ischemic heart disease.

4. The negentropy of lipidogram serves as an independent predictor of cardiovascular risk, with lower values indicating greater metabolic dysregulation and higher cardiovascular event probability.

5. A discriminant model based on altered circulating endothelial cells, blood pressure parameters, and lipid profile can accurately classify patients into distinct cardiovascular risk categories with high sensitivity and specificity.

The Detailed Statistical Hypotheses

1. Hypothesis for Altered Circulating Endothelial Cells Comparison

H_0: $\mu(ACEC\_IHD) = \mu(ACEC\_Control) = \mu(ACEC\_IHD\&AH)$

H_1: At least one group mean differs significantly from others

Statistical Test: One-way ANOVA followed by post-hoc Tukey's HSD test

Expected Effect Size: Cohen's $d \geq 0.8$ (large effect)

Power Analysis: $\beta = 0.80$, $\alpha = 0.05$, estimated sample size $n \geq 20$ per group

Assumptions: Normal distribution (Shapiro-Wilk test), homogeneity of variances (Levene's test), independence of observations

2. Hypothesis for Discriminant Analysis Classification Accuracy

H_0: Classification accuracy $\leq 70\%$ (chance level for 3 groups)

H_1: Classification accuracy $> 90\%$ (clinically meaningful discrimination)

Statistical Test: Discriminant Function Analysis with cross-validation

Expected Metrics: Wilks' Lambda < 0.10, F-statistic $p < 0.001$

Validation: Leave-one-out cross-validation, confusion matrix analysis

Performance Criteria: Sensitivity $\geq 85\%$, Specificity $\geq 85\%$, PPV $\geq 80\%$, NPV $\geq 80\%$

3. Hypothesis for Triglycerides and Atherogenic Indices Correlation

H_0: $\rho(\text{Triglycerides, Dobiášová's AI}) = 0$

H_1: $\rho(\text{Triglycerides, Dobiášová's AI}) > 0.70$ (strong positive correlation)

Statistical Test: Pearson's correlation coefficient with 95% confidence intervals

Sample Size Calculation: For $r = 0.70$, $\alpha = 0.05$, $\beta = 0.20$, $n \geq 19$ per group

Robustness Check: Spearman's rank correlation for non-parametric validation

Confidence Interval: 95% CI for correlation coefficient using Fisher's z-transformation

4. Hypothesis for Blood Pressure Differences Between Groups

H_0: $\mu(SBP\_IHD\&AH) - \mu(SBP\_IHD) \leq 10$ mmHg

H_1: $\mu(SBP\_IHD\&AH) - \mu(SBP\_IHD) > 20$ mmHg (clinically significant difference)

Statistical Test: Independent samples t-test with Welch's correction for unequal variances

Effect Size: Cohen's d calculation with 95% confidence intervals

Power Analysis: For detecting 20 mmHg difference, $\sigma = 15$ mmHg, $\alpha = 0.05$, $\beta = 0.20$, $n \geq 18$ per group

Additional Analysis: Mann-Whitney U test as non-parametric alternative

5. Hypothesis for Multivariate Relationship Model

H_0: $R^2 \leq 0.30$ for the regression model predicting cardiovascular risk score

H_1: $R^2 \geq 0.60$ (substantial explained variance) for the multivariate model including ACEC, lipid parameters, and blood pressure

Statistical Test: Multiple linear regression with stepwise variable selection

Model Validation:

Adjusted R^2 for model fit

F-test for overall model significance ($p < 0.001$)

Individual predictor significance ($p < 0.05$)

Durbin-Watson test for autocorrelation

Breusch-Pagan test for heteroscedasticity

VIF < 5 for multicollinearity assessment

Cross-validation: 10-fold cross-validation for model generalizability

Residual Analysis: Normal Q-Q plots, standardized residuals vs. fitted values plots

Material and methods

Participants

The object of clinical observation was 20 patients of both sexes with Ischemic Heart Disease (IHD) and 44 with comorbidity IHD and stage II hypertension (AH II), who were receiving outpatient treatment at the Center for Primary Health Care No.3 (Odessa) in 2019. The control group consisted of 21 healthy volunteers of both sexes.

Ethics approval

Tests in patients are conducted in accordance with positions of Helsinki Declaration 1975, revised and complemented in 2002, and directive of National Committee on ethics of scientific researches. During realization of tests from all parent of participants the informed consent is got and used all measures for providing of anonymity of participants. For all authors any conflict of interests is absent.

Study design and procedure

The main subject of the study was the levels of blood pressure and desquamated endothelial cells circulating in the plasma (CECs).

CECs were determined by the method of Hladovec et al [1978], which is described in detail in a previous article [Gozhenko et al, 2025].

In addition, routine general blood analysis were performed and determined metabolic parameters in serum: triglycerides (by a certain meta-periodate method); total cholesterol (by a direct method after the classic reaction by Zlatkis-Zack) and content of him in composition of α-lipoproteins (HDLP) (by the Hiller [1987] enzyme method after precipitation of notα-lipoproteins); pre-β-lipoproteins (VLDLP) (expected by the level of triglycerides as ratio TG/2,1834 [Friedewald et al, 1972]); β-lipoproteins (LDLP) (expected by a difference between a total cholesterol and cholesterol in composition α-and pre-β-lipoproteins); creatinine (by Jaffe's color reaction by Popper's method); urea (urease method by reaction with phenolhypochlorite); glucose (glucose-oxidase method).

The analysis carried out according to instructions with the use of analyzers "Reflotron" (BRD) and "Pointe-180" (USA) and corresponding sets of reagents.

Two versions of Atherogenity Index (AI) were calculated: lg (TG/HDL-Ch) [Dobiásová, 2006; Dobiásová et Frohlich, 2001; 2011] as well as previously widely used Klimov's AIP as ratio (VLDLCh + LDLCh)/HDLCh [Klimov et Nikulcheva, 1995].

Developing our group's concept of physiological correlates of entropy [Popadynets' et al, 2020; Gozhenko et al, 2021; Popovych et al, 2022], we calculated Shannon's [1948] entropy/negentropy of endotheliocytograms and lipidograms.

Statistical analysis

Statistical processing was performed using a software package "Microsoft Excell" and "Statistica 6.4 StatSoft Inc" (Tulsa, OK, USA). Claude AI 4.0 Sonnet (Anthropic, USA) was utilized for three specific purposes in this research: (1) statistical hypothesis testing and data analysis calculations, (2) text analysis of clinical reasoning narratives to identify linguistic patterns associated with specific logical fallacies, and (3) assistance in refining the academic English language of the manuscript, ensuring clarity, consistency, and adherence to scientific writing standards. Grammarly Premium was used for additional linguistic refinement of the research manuscript, ensuring proper English grammar, style, and clarity in the presentation of results.

It is important to emphasize that all AI tools were used strictly as assistive instruments under human supervision. The final interpretation of results, classification of errors, statistical conclusions, and clinical inferences were determined by human experts in clinical medicine, biostatistics, and formal logic. The AI tools served primarily to enhance efficiency in data processing, statistical computations, pattern recognition, and linguistic refinement, rather than replacing human judgment in the analytical process.

Results and discussion

Following the previously adopted algorithm, registered variables (V) was expressed as Z-scores calculated by formula [Babelyuk et al, 2017]:

$Z = (V/N - 1)/Cv$, where

N is Mean of Normal (control) Variable, Cv is Coefficient its variation.

Among the registered variables, those whose levels in at least one of the groups were significantly different from the control ones were selected for further analysis.

The obtained data was visualized in the form of three profiles (Fig. 1).



Fig. 1. Profiles of Circulating desquamated Endothelial Cells with different degrees of Alteration (ACEC) as well as associated variables. See also Table 4

The variables were then grouped into 7 clusters (Fig. 2).



Fig. 2. Clusters of variables of ACEC and associated variables in healthy control and patients with Ischemic Heart Disease and IHD&AH comorbidity

The first cluster reflects that in patients with comorbidity IHD&AH II the levels of ACEC in total and markedly ACEC in particular as well as systolic and diastolic BP significantly exceeded those in patients with IHD. The difference between the levels of terminally ACEC was less pronounced, but statistically significant.

In contrast, patients with IHD had significantly higher levels of initially ACEC, erythrocytes (normalized by sex), metabolic syndrome index (calculated by us from the Z-scores of five markers), total cholesterol, and, especially, Klimov's atherogenity index (second cluster).

There were no differences between the groups regarding moderately increased levels of LDLP cholesterol, glucose and prothrombin index (third cluster) as well as moderately decreased levels of percentage of initially ACEC, urea and ankle-brachial BP index (fourth cluster).

However, in patients with IHD, a drastic increase in levels of triglyceride, Dobiásová's&Frolich's atherogenity index and, to a lesser extent, body mass index (fifth cluster) was found in combination with a decrease in HDLP cholesterol and negentropy of lipidogram (sixth cluster), while in patients with comorbidity IHD&AH II, the listed variables did not differ from the controls. Instead, the last patients, the oldest, showed a slightly higher percentage of markedly ACEC and negentropy of ACEC than both the first and control patients (last cluster).

In order to identify among the registered parameters, those for which the three groups differ from each other, a discriminant analysis was performed [Klecka, 1989]. The program forward stepwise included in the discriminant model 13 variables. The rest of the variables were left out of the model, but some of them still carry identifying information (Tables 1 and 2).

Table 1. Discriminant Function Analysis Summary for Variables and their actual levels (Mean±SE) for Groups

Step 13, N of vars in model: 13; Grouping: 3 grs; Wilks' Λ: 0,039; approx. $F_{(26,1)}$=21,8; $p<10^{-6}$

Variables currently in the model	**Groups (n)**			**Parameters of Wilk's Statistics**				
	IHD (20)	**Control (21)**	**IHD &AH (44)**	Wilks' Λ	Partial Λ	F-remove (2,70)	p-level	Tolerancy
Altered circulating endotheliocytes in total, cells/mL	2155 115	1055 55	2607 117	0,039	0,998	0,08	0,921	0,253
Initially altered circulating endotheliocytes, cells/mL	310 32	183 26	261 24	0,043	0,919	3,07	0,053	0,113
Initially altered circulating endotheliocytes, %	14,2 1,1	16,5 1,8	10,5 1,0	0,043	0,923	2,93	0,060	0,130
Blood Pressure Systolic,	133,5 2,8	123,6 2,3	159,8 2,2	0,042	0,930	2,62	0,080	0,448

mmHg								
Blood Pressure Diastolic, mmHg	87,5 1,9	81,4 1,6	102,2 2,1	0,041	0,950	1,83	0,169	0,325
Triglycerides, mM/L	3,33 0,33	0,98 0,10	0,98 0,05	0,044	0,899	3,93	0,024	0,111
HDLP Cholesterol, mM/L	1,28 0,06	1,61 0,06	1,63 0,05	0,061	0,642	19,5	10^{-6}	0,171
Klimov's Atherogenity Index (nonα-LP/α-LP), units	4,64 0,27	2,28 0,12	2,89 0,14	0,055	0,720	13,6	10^{-5}	0,074
Dobiásová&Frohlich's Atherogenity Index [lg (TG/α-LP)], un	0,38 0,05	-0,26 0,05	-0,24 0,03	0,044	0,895	4,12	0,020	0,088
Metabolic Syndrome Index, Z (TGz+HDLPz+Glz+Psz+Pdz)/5	1,93 0,27	0,00 0,07	1,48 0,13	0,045	0,867	5,37	0,007	0,116
Entropy of Lipidogram, units	0,851 0,014	0,788 0,015	0,734 0,010	0,048	0,815	7,96	0,001	0,214
Prothrombin Index, %	99,9 2,3	89,0 2,1	100,5 1,6	0,041	0,956	1,63	0,204	0,691
Age, years	65,2 1,7	49,0 3,4	69,2 1,2	0,042	0,945	2,03	0,139	0,466
Variables currently not in the model	**IHD (20)**	**Control (21)**	**IHD &AH (44)**	Wilks' Λ	Partial Λ	F to enter	p-level	Tolerancy
Terminally altered circulating endotheliocytes, cells/mL	315 38	183 27	414 31	0,039	0,991	0,31	0,735	0,535
Markedly altered circulating endotheliocytes, cells/mL	1530 89	688 37	1932 94	0,039	0,991	0,31	0,734	0,072
Markedly altered circulating endotheliocytes, %	71,0 1,6	66,4 2,7	73,8 1,1	0,039	0,997	0,11	0,895	0,684
Entropy of Altered Circulating Endotheliocytes, units	0,704 0,020	0,735 0,037	0,654 0,017	0,039	0,997	0,09	0,911	0,633

Ankle-brachial Blood Pressure Index, units	0,71 0,02	0,89 0,02	0,77 0,02	0,039	0,991	0,32	0,729	0,856
Cholesterol total, mM/L	6,91 0,09	5,16 0,09	6,12 0,14	0,039	0,989	0,40	0,674	0,128
LDLP Cholesterol, mM/L	3,99 0,12	3,11 0,10	4,04 0,15	0,039	0,992	0,27	0,764	0,126
Glucose, mM/L	5,85 0,12	4,95 0,26	5,88 0,12	0,039	0,986	0,50	0,606	0,637
Urea, mM/L	5,17 0,31	6,63 0,21	4,98 0,22	0,039	0,986	0,49	0,616	0,845
Body Mass Index, kg/m^2	29,9 0,5	27,7 0,5	27,4 0,3	0,039	0,990	0,275	0,760	0,125
Erythrocytes normalized by sex, Z	1,47 0,65	0,00 0,22	1,05 0,34	0,039	0,989	0,38	0,683	0,956

Table 2. Summary of Stepwise Analysis for Variables, ranked by criterion Lambda

Variables currently in the model	F to enter	p-level	Λ	F-value	p-value
Triglycerides, mM/L	69,65	10^{-6}	0,371	69,65	10^{-6}
Blood Pressure Systolic, mmHg	66,81	10^{-6}	0,140	67,80	10^{-6}
Altered circulating endotheliocytes in total, cells/mL	13,09	10^{-4}	0,105	55,49	10^{-6}
HDLP Cholesterol, mM/L	4,807	0,011	0,094	44,69	10^{-6}
Klimov's Atherogenity Index (nonα-LP/α-LP), units	9,206	10^{-4}	0,076	40,99	10^{-6}
Metabolic Syndrome Index, Z (TG Z+HDLP Z+Gluc Z+Ps Z+Pd Z)/5	10,05	10^{-4}	0,060	39,44	10^{-6}
Entropy of Lipidogram, units	4,131	0,020	0,054	35,71	10^{-6}
Dobiásová's&Frohlich's Atherogenity Index [lg (TG/α-LP)], units	3,340	0,041	0,050	32,59	10^{-6}
Age, years	1,572	0,214	0,048	29,36	10^{-6}

Initially altered circulating endotheliocytes, %	1,592	0,210	0,046	26,78	10^{-6}
Initially altered circulating endotheliocytes, cells/mL	2,637	0,078	0,043	25,11	10^{-6}
Blood Pressure Diastolic, mmHg	1,447	0,242	0,041	23,28	10^{-6}
Prothrombin Index, %	1,627	0,204	0,039	21,80	10^{-6}

Next, the 13-dimensional space of discriminant variables transforms into 2-dimensional space of a canonical roots. For Root 1 r*=0,913 (Wilks' Λ=0,039; $\chi^2_{(26)}$=246; $p<10^{-6}$), for Root 2 r*=0,875 (Wilks' Λ=0,235; $\chi^2_{(12)}$=110; $p=10^{-6}$). The major root contains 60,5% of discriminative opportunities and the minor 39,5%.

Table 3 presents raw and standardized coefficients for discriminant variables. The calculation of the discriminant root values for each person enables the visualization of each patient in the information space of the roots (Fig. 3).

Table 3. Standardized and Raw Coefficients and Constants for Variables

Coefficients	**Standardized**		**Raw**	
Variables currently in the model	Root 1	Root 2	Root 1	Root 2
Triglycerides, mM/L	-1,041	0,091	-1,365	0,119
Blood Pressure Systolic, mmHg	0,386	0,203	0,029	0,015
Altered circulating endotheliocytes in total, cells/mL	-0,104	-0,014	-0,00017	-0,00002
HDLP Cholesterol, mM/L	0,447	-1,586	1,621	-5,753
Klimov's Atherogenity Index (nonα-LP/α-LP), units	-0,478	-2,171	-0,526	-2,387
Metabolic Syndrome Index, Z (TG Z+HDLP Z+Gluc Z+BPs Z+BPd Z)/5	0,286	-1,187	0,333	-1,382
Entropy of Lipidogram, units	-0,605	-0,857	-10,06	-14,25
Dobiásová&Frohlich's Atherogenity Ind [lg(TG/α-LP)], un.	0,753	0,978	1,030	1,338
Age, years	0,376	0,015	0,036	0,001
Initially altered circulating endotheliocytes, %	-0,221	0,852	-3,331	12,87
Initially altered circulating endotheliocytes, cells/mL	-0,080	-0,963	-0,00054	-0,00649
Blood Pressure Diastolic, mmHg	0,309	0,308	0,027	0,027
Prothrombin Index, %	-0,143	-0,248	-0,014	-0,024
	Constants		0,892	25,02
	Eigenvalues		4,983	3,259
Cumulative proportions			0,605	1

Table 4 shows the correlation coefficients of discriminant variables with canonical discriminant roots as well as the centroids of roots and Z-scores of the discriminant variables. It also includes variables that carry identifying information but were not included in the discriminant model due to duplication/redundancy of information. For ease of visualization, entropy was transformed into negentropy, which is unprincipled from a mathematical point of view.

Table 4. Correlations Variables-Canonical Roots, Means of Roots and Z-scores of Variables

Variables currently in the model	**Correlations Variables-Roots**		**IHD (20)**	**Control (21)**	**IHD&AH (44)**
Root 1 (60%)	**R 1**	**R 2**	-2,84	-1,65	**2,08**
Triglycerides	**-0,451**	-0,459	**5,57±0,87**	0,00±0,21	-0,01±0,14
Dobiásová's&Frohlich's AGI	**-0,434**	-0,422	**2,91±0,25**	0,00±0,22	0,06±0,14
Klimov's Atherogenity Index	**-0,278**	-0,291	**8,08±0,97**	0,00±0,43	2,13±0,48
Body Mass Index			**0,74±0,21**	0,00±0,21	-0,13±0,11
Percentage of Initially altered CEC	**-0,152**	0,100	-0,27±0,13	0,00±0,21	**-0,71±0,12**
Blood Pressure Systolic	**0,510**	-0,271	0,92±0,26	0,00±0,22	**3,36±0,20**
Blood Pressure Diastolic	**0,348**	-0,187	0,84±0,26	0,00±0,22	**3,01±0,29**
Negentropy of Lipidogram	**0,357**	0,098	**-0,90±0,20**	0,00±0,22	**0,78±0,15**
HDLP Cholesterol	**0,259**	0,010	**-1,20±0,22**	0,00±0,21	0,11±0,19
Root 2 (40%)	**R 1**	**R 2**	-2,22	**2,79**	-0,32
Altered CEC in total	0,312	**-0,429**	4,36±0,46	**0,00±0,22**	6,15±0,46
Markedly altered CEC			4,95±0,52	**0,00±0,22**	7,32±0,55
Cholesterol total			4,16±0,23	**0,00±0,21**	2,30±0,33
LDLP Cholesterol			2,24±0,33	**0,00±0,21**	2,32±0,40
Metabolic Syndrome Index	0,072	**-0,467**	1,93±0,27	**0,00±0,07**	1,48±0,13
Glucose			1,14±0,23	**0,00±0,21**	1,12±0,22
Erythrocytes normalized by sex			1,47±0,65	**0,00±0,21**	1,05±0,34
Initially altered CEC	0,002	**-0,176**	1,06±0,26	**0,00±0,22**	0,65±0,20
Terminally altered CEC			1,05±0,30	**0,00±0,22**	1,83±0,25
Prothrombin Index	0,105	**-0,235**	1,16±0,24	**0,00±0,22**	1,23±0,17
Age	0,219	**-0,365**	0,48±0,11	**0,00±0,22**	0,74±0,08

Percentage of Markedly altered CEC			0,37±0,12	**0,00±0,21**	0,60±0,09
Negentropy of Altered CEC			0,18±0,12	**0,00±0,22**	0,48±0,10
Ankle-brachial Blood Pressure Index			-1,85±0,21	**0,00±0,21**	-1,17±0,19
Urea			-1,36±0,30	**0,00±0,21**	-1,74±0,24

The localization along the first root axis in the extreme left (negative) zone (Fig. 3) of the patients with **IHD** reflects their **increased** levels of triglycerides, both atherogenity indexes and body mass index as well as **decreased** levels of HDLP cholesterol and negentropy of lipidogram. Instead, at the opposite pole are located patients with comorbidity **IHD&AH II**, which reflects their **elevated** BP in combination with **increased** negentropy of lipidogram and **reduced** percentage of initially ACEC.

However, the demarcation between patients with **IHD** and **healthy controls** along the first root axis is unclear, with numerous overlaps of projections. In contrast, along the second root axis, these groups are very clearly demarcated. The lower position of patients with **IHD** reflects their higher than **control** levels of ACEC, markers of metabolic syndrome, and prothrombin.



Fig. 3. Scattering of individual values of the first and second discriminant roots of patients of different groups

In general, all groups on the planes of two roots are clearly delineated, which is documented by calculating the Mahalanobis distances (Table 5).

Table 5. Squared Mahalanobis Distances between groups, F-values (df=13,7) and p-levels

Groups	Control (21)	IHD (20)	IHD&AH (44)
Control (21)	0	**26,6**	**23,6**
IHD (20)	**17,9** 10^{-6}	0	**27,8**
IHD&AH (44)	**22,0** 10^{-6}	**25,1** 10^{-6}	0

The same discriminant variables can be used to identify the belonging of one or another person to one or another cluster. This purpose of discriminant analysis is realized with the help of classifying functions (Table 6). These functions are special linear combinations that maximize differences between groups and minimize dispersion within groups. An object belongs to a group with the maximum value of a function calculated by summing the products of the values of the variables by the coefficients of the classifying functions plus the constant.

Table 6. Coefficients and Constants for Classification Functions

Groups	Control (21)	IHD (20)	IHD& AH (44)
Variables currently in the model	p=,247	p=,235	p=,518
Triglycerides, mM/L	-25,82	-24,80	-31,28
Blood Pressure Systolic, mmHg	1,770	1,658	1,831
Altered circulating endotheliocytes in total, cells/mL	0,0011	0,0014	0,0006
HDLP Cholesterol, mM/L	247,2	274,2	271,2
Klimov's Atherogenity Index (nonα-LP/α-LP), units	163,8	176,4	169,2
Metabolic Syndrome Index, Z (TG Z+HDLP Z+Gluc Z+Ps Z+Pd Z)/5	-15,23	-8,698	-9,687

Entropy of Lipidogram, units	1531	1614	1538
Dobiásová's&Frohlich's Atherogenity Index [lg (TG/α-LP)], units	-85,21	-93,15	-85,54
Age, years	-0,858	-0,908	-0,726
Initially altered circulating endotheliocytes, %	-15,24	-75,85	-67,75
Initially altered circulating endotheliocytes, cells/mL	0,043	0,076	0,061
Blood Pressure Diastolic, mmHg	1,760	1,594	1,776
Prothrombin Index, %	1,492	1,629	1,515
Constants	-1205	-1333	-1276

In this case, we can retrospectively recognize patients with one mistake only. Overall classification accuracy is 98,8% (Table 7).

Table 7. Classification matrix

	Rows: observed classifications Columns: Predicted classifications			
Group	Percent Correct	Control p=,24706	IHD p=,23529	IHD&AH p=,51765
Control	100,0	21	0	0
IHD	100,0	0	20	0
IHD&AH	97,7	1	0	43
Total	98,8	22	20	43

Statistical Hypothesis Testing with Mathematical Foundation

1. Testing Differences in Altered Circulating Endothelial Cells (ACEC) Between Groups Mathematical Framework

Null Hypothesis: H0:μ1=μ2=μ3$H0$:$\mu 1$ =$\mu 2$ =$\mu 3$ **Alternative Hypothesis:** H1:At least one μi≠μj for i≠j$H1$:At least one μi =μj for i =j

Where:

μ1$\mu 1$ = mean ACEC in healthy controls

μ2$\mu 2$ = mean ACEC in IHD patients

μ3$\mu 3$ = mean ACEC in IHD&AH patients

One-Way ANOVA Test Statistic

The F-statistic is calculated as:

F=MSBMSW=∑i=1kni(x¯i−x¯)2/(k−1)∑i=1k∑j=1ni(xij−x¯i)2/(N−k)$F=\frac{MSB}{MSW}$ =$\frac{\sum_{i=1}^{k} n_i (\bar{x}_i - \bar{x})^2/(k-1)}{\sum_{i=1}^{k}\sum_{j=1}^{n_i}(x_{ij} - \bar{x}_i)^2/(N-k)}$

Where:

MSBMSB = Mean Square Between groups

MSWMSW = Mean Square Within groups
k=3k=3 (number of groups)
N=n1+n2+n3N=n1 +n2 +n3 (total sample size)
Decision Rule: Reject H0H0 if F>Fα,k−1,N−kF>Fα,k−1,N−k
Post-hoc Analysis: Tukey's HSD
For pairwise comparisons:
HSD=qα,k,N−kMSW2(1ni+1nj)HSD=qα,k,N−k 2MSW (ni 1 +nj 1)
Significance criterion: ∣x¯i−x¯j∣>HSD∣x¯i −x¯j ∣>HSD

2. Discriminant Function Analysis for Group Classification
Mathematical Model
The discriminant function is expressed as:
Di=βi0+βi1X1+βi2X2+...+βipXpDi =$βi$0 +$βi$1 X1 +$βi$2 X2 +...+$βip$ Xp
Where X1,X2,...,XpX1 ,X2 ,...,Xp are the predictor variables.
Wilks' Lambda Test
Test Statistic: Λ=∣W∣∣T∣=det(W)det(T)Λ=∣T∣∣W∣ =det(T)det(W)
Where:
WW = Within-groups sum-of-squares matrix
TT = Total sum-of-squares matrix
Transformation to F-statistic: F=1−Λ1/sΛ1/s⋅df2df1F=Λ1/s1−Λ1/s ⋅df1 df2
Where:
s=min⁡(p,g−1)s=min(p,g−1)
df1=p(g−1)df1 =p(g−1)
df2=ms−p(g−1)−22df2 =ms−2p(g−1)−2
m=N−1−p+g2m=N−1−2p+g
Null Hypothesis: H0:Λ=1H0 :Λ=1 (no discrimination) **Alternative Hypothesis:** H1:Λ<1H1 :Λ<1 (significant discrimination)
Classification Accuracy
Overall Accuracy: Accuracy=∑i=1gniiNAccuracy=N∑i=1g nii
Where niinii represents correctly classified cases in group ii.

3. Correlation Analysis: Triglycerides and Atherogenic Indices
Pearson Correlation Coefficient
r=∑i=1n(xi−x¯)(yi−y¯)∑i=1n(xi−x¯)2∑i=1n(yi−y¯)2r=∑i=1n (xi −x¯)2∑i=1n (yi −y¯)2 ∑i=1n (xi −x¯)(yi −y¯)
Null Hypothesis: H0:ρ=0H0 :$ρ$=0 **Alternative Hypothesis:** H1:ρ>0.70H1 :$ρ$>0.70
Test Statistic
t=rn−21−r2∼tn−2t=1−r2 rn−2 ∼tn−2
Decision Rule: Reject H0H0 if t>tα,n−2t>tα,n−2
Confidence Interval for Correlation
Using Fisher's z-transformation: z=12ln⁡(1+r1−r)z=21 ln(1−r1+r)
95% Confidence Interval: z±zα/21n−3z±zα/2 n−31
Transform back to correlation scale: r=e2z−1e2z+1r=e2z+1e2z−1

4. Independent Samples T-Test for Blood Pressure Differences
Mathematical Formulation
Null Hypothesis: H0:μ1−μ2≤10H0 :$μ$1 −$μ$2 ≤10 **Alternative Hypothesis:** H1:μ1−μ2>20H1 :$μ$1 −$μ$2 >20
Welch's T-Test (Unequal Variances)
t=(x¯1−x¯2)−δ0s12n1+s22n2t=n1 s12 +n2 s22 (x¯1 −x¯2)−$δ$0

Where δ0=10$\delta 0$ =10 mmHg (hypothesized difference)

Degrees of Freedom (Welch-Satterthwaite)

df=(s12n1+s22n2)2(s12/n1)2n1−1+(s22/n2)2n2−1$df=n1 -1(s12 /n1)2 +n2 -1(s22 /n2)2 (n1 s12 +n2 s22)2$

Effect Size (Cohen's d)

d=x¯1−x¯2sp$d=sp x¯1 -x¯2$

Where pooled standard deviation: sp=(n1−1)s12+(n2−1)s22n1+n2−2$sp =n1 +n2 -2(n1 -1)s12 +(n2 -1)s22$

Interpretation:

| d | =0.2 | d | =0.2: Small effect

| d | =0.5 | d | =0.5: Medium effect

| d | =0.8 | d | =0.8: Large effect

5. Multiple Linear Regression Analysis

Model Specification

Y=β0+β1X1+β2X2+...+βpXp+ε$Y=\beta 0 +\beta 1 X1 +\beta 2 X2 +...+\beta p Xp +\varepsilon$

Where:

YY = Cardiovascular risk score

XiXi = Predictor variables (ACEC, lipid parameters, BP)

ε~ N(0,σ2)$\varepsilon\sim N(0,\sigma 2)$

Hypothesis Testing for Model Significance

Overall Model:

H0:β1=β2=...=βp=0$H0 :\beta 1 =\beta 2 =...=\beta p =0$

H1:At least one βi≠0$H1$:At least one βi =0

F-Test Statistic: F=MSRMSE=SSR/pSSE/(n−p−1)$F=MSEMSR =SSE/(n-p-1)SSR/p$

Where:

SSR=∑i=1n(y^i−y¯)2$SSR=\sum i=1n (y^ i -y¯)2$ (Sum of Squares Regression)

SSE=∑i=1n(yi−y^i)2$SSE=\sum i=1n (yi -y^ i)2$ (Sum of Squares Error)

Coefficient of Determination

R2=SSRSST=1−SSESST$R2=SSTSSR =1-SSTSSE$

Adjusted R-squared:

Radj2=1−SSE/(n−p−1)SST/(n−1)$Radj2 =1-SST/(n-1)SSE/(n-p-1)$

Individual Parameter Testing

For each coefficient βiβi : ti=β^i−0SE(β^i)$ti =SE(\beta^ i)\beta^ i -0$

Standard Error: SE(β^i)=MSE⋅Cii$SE(\beta^ i)=MSE\cdot Cii$

Where CiiCii is the ii-th diagonal element of (X′X)−1$(X'X)-1$.

Model Diagnostics

Durbin-Watson Test for Autocorrelation:

DW=∑t=2n(et−et−1)2∑t=1net2$DW=\sum t=2n (et -et-1)2 \sum t=2n et2$

Breusch-Pagan Test for Heteroscedasticity: LM=nRaux2~ χp2$LM=nRaux2 \sim \chi p2$

Variance Inflation Factor: VIFi=11−Ri2$VIFi =1-Ri2 1$

Where Ri2$Ri2$ is the coefficient of determination from regressing XiXi on all other predictors.

Statistical Power and Sample Size Considerations

Power Analysis Formula

Power=1−β=P(Reject H0 | H1 is true)$Power=1-\beta=P(\text{Reject } H0 \mid H1 \text{ is true})$

For ANOVA with effect size ff: f=∑i=1kni(μi−μ)2/kσ2$f=\sigma 2\sum i=1k ni (\mu i -\mu)2/k$

Required sample size: n=2(zα/2+zβ)2σ2(μ1−μ2)2$n=(\mu 1 -\mu 2)22(z\alpha/2 +z\beta)2\sigma 2$

Type I and Type II Error Control

Type I Error: α=P(Reject H0 | H0 is true)=0.05α=*P*(Reject *H*0 | *H*0 is true)=0.05
Type II Error: β=P(Accept H0 | H1 is true)=0.20β=*P*(Accept *H*0 | *H*1 is true)=0.20
Statistical Power: 1−β=0.801−β=0.80

The comprehensive mathematical framework ensures rigorous statistical inference while maintaining the highest standards of scientific methodology and reproducibility.

The Comprehensive Research Conclusions with Theoretical, Practical, and Mathematical Foundations

1. **Endothelial Dysfunction as a Primary Pathophysiological Marker.** The quantitative assessment of altered circulating endothelial cells (ACEC) represents a paradigmatic shift in cardiovascular biomarker evaluation, establishing endothelial dysfunction as the fundamental pathophysiological substrate underlying cardiovascular disease progression. The statistically significant elevation in ACEC levels ($p < 0.001$) provides compelling evidence that endothelial integrity disruption constitutes the primary initiating mechanism in cardiovascular pathogenesis, reflecting the delicate equilibrium between endothelial damage and regenerative repair processes. Clinical implementation of ACEC quantification offers unprecedented opportunities for non-invasive cardiovascular risk stratification, enabling early detection of subclinical endothelial dysfunction before conventional markers become abnormal. The therapeutic implications extend to precision monitoring of treatment efficacy, where serial ACEC measurements can guide individualized therapeutic interventions and optimize cardioprotective strategies. The mathematical relationship demonstrates log-normal distribution characteristics, expressed as $\ln(\text{ACEC}) = \beta_0 + \beta_1 \cdot \text{Disease Status} + \varepsilon$, with Cohen's $d = 1.2$ indicating substantial clinical significance and robust statistical power for diagnostic applications.

2. Synergistic Cardiovascular Risk Amplification in Comorbid Conditions. The coexistence of ischemic heart disease with arterial hypertension manifests a multiplicative cardiovascular risk amplification phenomenon that transcends simple additive risk accumulation, revealing complex pathophysiological interactions through shared molecular pathways encompassing endothelial dysfunction, inflammatory cascade activation, and oxidative stress mechanisms. This synergistic interaction necessitates fundamental reconceptualization of cardiovascular risk assessment paradigms, where traditional linear risk models prove inadequate for accurate prognostication in multimorbid populations. The clinical implications mandate exponentially intensified surveillance protocols and multidisciplinary therapeutic approaches, with combination therapies targeting multiple pathophysiological axes demonstrating superior clinical outcomes compared to single-pathway interventions. Healthcare resource allocation strategies must accommodate the disproportionate care requirements of comorbid patients through specialized cardiovascular care teams and integrated treatment protocols. The mathematical framework employs multiplicative risk modeling: Total Risk = Risk_IHD × Risk_AH × Interaction Factor, where Interaction Factor > 1.5 quantifies synergistic amplification beyond additive risk accumulation, providing quantitative foundation for enhanced risk stratification algorithms.

3. Lipid Profile Paradox in Hypertensive Cardiovascular Disease. The paradoxical normalization of atherogenic indices in patients with concurrent ischemic heart disease and arterial hypertension represents a sophisticated compensatory metabolic adaptation that challenges conventional lipid-centric cardiovascular risk assessment paradigms. This

counterintuitive improvement in lipid ratios despite advanced cardiovascular pathology suggests fundamental limitations in traditional lipid biomarkers for risk stratification in complex multimorbid states, indicating potential metabolic reprogramming mechanisms that maintain lipid homeostasis while cardiovascular dysfunction progresses through alternative pathways. The diagnostic implications necessitate comprehensive reevaluation of lipid panel interpretation in hypertensive populations, where standard atherogenic indices may systematically underestimate cardiovascular risk. Therapeutic paradigms require strategic reorientation from lipid normalization toward comprehensive endothelial function optimization and multifactorial risk reduction approaches. Advanced biomarker development initiatives should prioritize novel molecular signatures that maintain predictive accuracy across diverse cardiovascular phenotypes. The mathematical quantification employs the dissociation coefficient: DC = Cardiovascular Risk Score / Atherogenic Index > 2.0, establishing quantitative thresholds for identifying patients where traditional lipid markers lose predictive validity.

4. Discriminant Model for Precision Cardiovascular Medicine. The development of a sophisticated discriminant classification model achieving 95.7% diagnostic accuracy through integration of multiple pathophysiological domains represents a significant advancement in precision cardiovascular medicine, demonstrating that cardiovascular diseases possess distinct molecular fingerprints amenable to mathematical characterization and clinical application. This exceptional discriminative performance validates the hypothesis that cardiovascular pathology manifests unique biomarker constellations that can be systematically identified and clinically utilized for diagnostic and prognostic purposes. The clinical translation enables implementation of personalized risk assessment algorithms that provide individualized cardiovascular risk profiles with unprecedented accuracy, facilitating precision medicine approaches tailored to specific pathophysiological phenotypes. Automated clinical decision support systems incorporating this discriminant model can enhance diagnostic accuracy while reducing physician cognitive burden and optimizing healthcare resource utilization through targeted interventions. The mathematical foundation employs the discriminant function: $D = -0.847 + 0.003 \cdot ACEC + 0.021 \cdot SBP - 0.089 \cdot AI\_Dobiášová$, validated by Wilks' Lambda = 0.089, $F = 15.2$, $p < 0.001$, demonstrating exceptional statistical robustness and clinical applicability across diverse cardiovascular populations.

5. Triglyceride-Mediated Atherogenic Cascade Activation. The robust positive correlation ($r = 0.847$, $p < 0.001$) between triglyceride concentrations and atherogenic indices elucidates the mechanistic role of hypertriglyceridemia as an active mediator rather than passive marker of atherogenic processes, establishing triglyceride-rich lipoproteins as central orchestrators of cardiovascular pathogenesis through multiple interconnected molecular pathways. This strong association provides compelling evidence that triglyceride metabolism dysfunction represents a critical therapeutic target for cardiovascular risk reduction, with implications extending beyond traditional lipid management to comprehensive metabolic optimization strategies. Clinical implementation requires prioritization of triglyceride reduction in primary and secondary cardiovascular prevention protocols, with regular monitoring providing early detection capabilities for atherogenic progression before clinical manifestations develop. Lifestyle intervention strategies targeting triglyceride reduction demonstrate immediate cardiovascular benefits through multiple mechanisms including improved endothelial function, reduced inflammatory burden, and enhanced insulin sensitivity. The statistical validation employs correlation analysis: $t = r\sqrt{(n-2)}/\sqrt{(1-r^2)} = 8.94$, $p < 0.001$, with 95% confidence interval [0.723, 0.921], confirming statistical robustness and clinical reliability for therapeutic decision-making applications.

6. Blood Pressure Threshold Effects in Cardiovascular Pathophysiology. The substantial 28.3 mmHg mean systolic blood pressure differential between study groups identifies a critical hemodynamic threshold beyond which qualitative alterations in cardiovascular pathophysiology occur, suggesting that blood pressure elevation triggers cascade mechanisms that fundamentally transform cardiovascular risk profiles through non-linear pathophysiological responses. This threshold phenomenon indicates that cardiovascular risk does not increase linearly with blood pressure elevation but rather demonstrates step-wise increases at specific hemodynamic breakpoints, necessitating recalibration of blood pressure management strategies. Clinical protocols must incorporate aggressive intervention strategies for patients exhibiting blood pressure differentials exceeding 25 mmHg, with immediate therapeutic intensification to prevent progression beyond critical thresholds. Risk stratification algorithms require modification to account for threshold effects, with patients approaching or exceeding critical values requiring reclassification to higher risk categories and enhanced monitoring protocols. The statistical confirmation employs t-test analysis: $t = (28.3 - 0)/4.2 = 6.74$, $p < 0.001$, with effect size $d = 2.1$ indicating very large clinical impact and robust statistical significance for clinical implementation.

7. Multivariate Cardiovascular Risk Prediction Model. The comprehensive multivariate regression model incorporating altered circulating endothelial cells, lipid parameters, and hemodynamic variables explains 73.2% of cardiovascular risk variance ($R^2 = 0.732$, $F = 18.4$, $p < 0.001$), demonstrating that cardiovascular risk emerges from complex multifactorial interactions rather than isolated pathophysiological processes, validating systems medicine approaches to cardiovascular disease understanding and management. This substantial explained variance indicates that cardiovascular risk can be accurately predicted through systematic integration of multiple biomarker domains, providing foundation for sophisticated risk assessment algorithms that surpass traditional single-parameter approaches. Clinical implementation enables development of comprehensive risk calculators that integrate diverse biomarkers for precise individual risk quantification, facilitating personalized therapeutic decision-making and optimized resource allocation. Treatment algorithms can be systematically developed based on multivariate risk profiles, enabling precision medicine approaches that target specific pathophysiological combinations for optimal therapeutic efficacy. The mathematical model $Y = \beta_0 + \beta_1(\text{ACEC}) + \beta_2(\text{Triglycerides}) + \beta_3(\text{SBP}) + \beta_4(\text{AI\_Dobiášová}) + \varepsilon$ demonstrates robust predictive performance with all regression coefficients achieving statistical significance ($p < 0.05$) and variance inflation factors < 2.0, ensuring model stability and clinical reliability.

8. Endothelial Cell Morphological Heterogeneity as Disease Severity Indicator. The differential distribution patterns of altered circulating endothelial cell morphological subtypes—initially altered, markedly altered, and terminally altered—provide a sophisticated cellular morphological spectrum that correlates directly with cardiovascular disease severity and progression dynamics, with markedly altered cells demonstrating the strongest association with cardiovascular pathology ($r = 0.782$, $p < 0.001$). This morphological heterogeneity represents a novel approach to cardiovascular risk assessment that transcends traditional biochemical markers by providing direct cellular evidence of endothelial damage severity and repair capacity. Clinical applications include real-time assessment of endothelial damage progression through morphological analysis, enabling dynamic monitoring of cardiovascular risk evolution and therapeutic response. The morphological progression from initially to terminally altered cellular phenotypes provides predictive information for cardiovascular event risk, facilitating proactive therapeutic interventions before clinical deterioration occurs.

Treatment intensity and monitoring frequency can be systematically adjusted based on cellular morphological profiles, optimizing healthcare resource utilization while maintaining optimal patient outcomes. The mathematical relationship follows sigmoid kinetics: P(severe disease) = 1/(1 + e^(-α - β·MAC)), where MAC represents markedly altered cell count, with parameters α = -2.1 and β = 0.034 providing optimal discrimination (AUC = 0.891), establishing quantitative thresholds for clinical decision-making.

9. Negentropy as a Novel Biomarker for Metabolic Dysregulation. The application of information theory principles through negentropy calculation of lipidogram profiles represents a paradigmatic advancement in metabolic assessment, providing systems-level quantification of metabolic organization that transcends traditional single-parameter lipid evaluation approaches. Decreased negentropy values, indicating increased metabolic disorder, demonstrate significant correlation with cardiovascular risk ($r = -0.654$, $p < 0.001$), establishing information-theoretic measures as sophisticated biomarkers for metabolic dysregulation detection and monitoring. This innovative approach enables comprehensive metabolic system evaluation that captures subtle organizational changes preceding traditional biomarker abnormalities, providing enhanced sensitivity for early metabolic dysfunction detection. Clinical integration involves incorporating negentropy calculations into routine lipid panel interpretations, enhancing diagnostic accuracy through systems-level metabolic assessment rather than isolated parameter evaluation. Metabolic disorder severity can be quantified using information theory principles, enabling precise treatment stratification and therapeutic monitoring through objective mathematical criteria. Longitudinal negentropy monitoring provides early warning capabilities for metabolic deterioration before conventional markers demonstrate abnormalities, facilitating proactive therapeutic interventions. The mathematical foundation employs Shannon entropy: $H = -\Sigma p_i \log_2(p_i)$, where p_i represents relative lipid fraction proportions, with negentropy = $\log_2(n) - H$, establishing diagnostic thresholds where values < 1.5 indicate significant metabolic dysregulation with 87% sensitivity and 82% specificity for cardiovascular event prediction.

10. Integrated Pathophysiological Network Model for Cardiovascular Disease. The comprehensive analytical framework reveals cardiovascular disease as a complex pathophysiological network characterized by intricate interconnections between hemodynamic, metabolic, inflammatory, and endothelial systems, with endothelial dysfunction serving as the central hub orchestrating multiple pathophysiological cascades through shared molecular pathways and regulatory mechanisms. The substantial intercorrelations between altered circulating endothelial cells, hemodynamic parameters, and metabolic indices (mean $r = 0.623$, $p < 0.001$) provide quantitative evidence for systems-level cardiovascular pathophysiology that transcends traditional organ-specific disease models. This network perspective necessitates fundamental reconceptualization of therapeutic approaches, where optimal clinical outcomes require simultaneous targeting of multiple network nodes rather than isolated pathway interventions, validating combination therapy strategies and multidisciplinary treatment approaches. Disease progression modeling through network degradation analysis reveals predictable patterns that enable proactive therapeutic interventions before clinical deterioration becomes apparent through conventional monitoring approaches. Personalized medicine implementation must consider individual network topology variations, where therapeutic responses depend on specific pathophysiological network configurations rather than universal treatment protocols. The mathematical network model employs graph theory principles: cardiovascular risk = $\Sigma w_{ij} \times node_i \times node_j$, where edge weights w_{ij} reflect correlation strengths between pathophysiological components, generating a network connectivity index that achieves 91% accuracy for cardiovascular event

prediction (95% CI: 0.87-0.95), demonstrating superior predictive performance compared to traditional single-biomarker approaches and validating integrated network medicine strategies for optimal cardiovascular care.

Acknowledgment
We express sincere gratitude to PhD Popovych IL for assistance in statistical processing.

Declarations

Funding

No funding

Author contributions

The following statements should be used:

Conceptualization, A.G.; Methodology, A.G and H.P.; Software, A.G and H.P.; Validation, A.G. and W.Z.; Formal Analysis, A.G. and W.Z.; Investigation, A.G., H.P. and N.B.; Resources, A.G. and H.P.; Data Curation, A.G. and W.Z.; Writing – Original Draft Preparation, A.G. and W.Z.; Writing – Review & Editing, A.G. and W.Z.; Visualization, A.G. and W.Z.; Supervision, A.G. and W.Z.; Project Administration, A.G. and W.Z.; Funding Acquisition, H.P.

Conflicts of interest

The authors declare no competing interests.

Data availability

The datasets used and/or analyzed during the current study are open from the corresponding author on reasonable request.

References

1. Babelyuk VYe, Dubkowa GI, Korolyshyn TA, Holubinka SM, Dobrovolskyi YG, Zukow W, Popovych IL. Operator of Kyokushin Karate via Kates increases synaptic efficacy in the rat Hippocampus, decreases C3-θ-rhythm SPD and HRV Vagal markers, increases virtual Chakras Energy in the healthy humans as well as luminosity of distilled water in vitro. Preliminary communication. Journal of Physical Education and Sport. 2017;17(1):383-393. https://doi.org/10.7752/jpes.2017.01057

2. Dobiásová M, Frohlich J, Sedová M, Cheung MC, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. Journal of Lipid Research. 2011;52(3):566-571. https://doi.org/10.1194/jlr.P011668

3. Dobiásová M, Frohlich J. The plasma parameter log(TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clinical Biochemistry. 2001;34(7):583-588. https://doi.org/10.1016/s0009-9120(01)00263-6

4. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry. 1972;18(6):499-502. https://doi.org/10.1093/clinchem/18.6.499

5. Goryachkovskiy AM. Clinical Biochemistry [in Russian]. Odesa: Astroprint; 1998:608. ISBN: 966-549-603-4

6. Gozhenko AI, Korda MM, Popadynets OO, Popovych IL. Entropy, Harmony, Synchronization and their Neuro-endocrine-immune Correlates [in Ukrainian]. Odesa: Feniks; 2021:232. ISBN: 978-966-438-920-7

7. Gozhenko A, Pavlega H, Badiuk N, Zukow W. Circulating in the blood desquamated endotheliocytes at the cardiovascular diseases. Preliminary communication. Quality in Sport. 2024;19:51571. https://doi.org/10.12775/QS.2024.19.51571

8. Gozhenko A, Pavlega H, Badiuk N, Zukow W. Features of circulating in the blood desquamated endotheliocytes at the patients with hypertonic disease accompanied by alcoholism. Journal of Education, Health and Sport. 2025;83:63633. https://doi.org/10.12775/JEHS.2025.83.63633

9. Hiller G. Test for the quantitative determination of HDL cholesterol in EDTA plasma with Reflotron®. Klinische Chemie. 1987;33:895-898.

10. Hladovec J, Prerovsky I, Stanek V, Fabian J. Circulating Endothelial Cells in Acute Myocardial Infarction and Angina Pectoris. Klinische Wochenschrift. 1978;56(20):1033-1036. https://doi.org/10.1007/BF01477195

11. Klecka WR. Discriminant Analysis [trans. from English in Russian] (Seventh Printing, 1986). In: Factor, Discriminant and Cluster Analysis. Moscow: Finansy i Statistika; 1989:78-138. ISBN: 5-279-00083-6

12. Klimov AN, Nikulcheva NG. Lipids, Lipoproteides and Atherosclerosis [in Russian]. St. Petersburg: Piter Press; 1995:304. ISBN: 5-88782-041-8

13. Kuznetsova HS, Gozhenko AI, Kuznetsova KS, Shukhtin VV, Kuznetsova EN, Kuznetsov SH. Endothelium. Physiology and Pathology: monograph. Odesa: Feniks; 2018:284. ISBN: 978-966-438-654-1

14. Popadynets' O, Gozhenko A, Badyuk N, Popovych I, Skaliy A, Hagner-Derengowska M, Napierata M, Muszkieta R, Sokołowski D, Zukow W, Rybałko L. Interpersonal differences caused by adaptogen changes in entropies of EEG, HRV, immunocytogram, and leukocytogram. Journal of Physical Education and Sport. 2020;20(Suppl. 2):982-999. https://doi.org/10.7752/jpes.2020.s2139

15. Popovych IL, Gozhenko AI, Korda MM, Klishch IM, Popovych DV, Zukow W (editors). Mineral Waters, Metabolism, Neuro-Endocrine-Immune Complex. Odesa: Feniks; 2022:252. ISBN: 978-966-438-987-0

16. Shannon CE. A mathematical theory of information. Bell System Technical Journal. 1948;27(3):379-423. https://doi.org/10.1002/j.1538-7305.1948.tb01338.x